Even after 5 yrs since its arrival, SARS-CoV-2 mutations keep emerging. A new variant LP.8.1 is rising. Almost 1 in 5 COVID cases in New South Wales are it. In the UK, it accounts for at least 3 in 5 cases. Just what is LP.8.1? Is it worrying? 1/
LP.8.1 was first detected in July 2024. It’s a descendant of Omicron, specifically of KP.1.1.3, which is descended from JN.1, a subvariant that caused large waves of COVID infections around the world in late 2023 and early 2024. 2/
The WHO designated LP.8.1 as a variant under monitoring in January. This was in response to its significant growth globally, and reflects that it has genetic changes which may allow the virus to spread more easily and pose a greater risk to human health. 3/
SARS-CoV-2 attaches to our cells via its spike protein, which LP.8.1 has six mutations in. One mutation, V445R, may let this variant spread faster than others. Lab tests demonstrate V445R increases lung cell binding. 4/
Notably, the symptoms of LP.8.1 don’t appear to be any more severe than other circulating strains. Current COVID vaccines, including the most recently available JN.1 shots, are still expected to offer good protection against symptomatic and severe disease with LP.8.1. 5/
That doesn’t mean cases won’t rise!
COVID remains a global health threat. Australia has had over 45,000 new cases this year, with 260 people in hospitals. Because many people no longer test or report infections, the true figure is likely far higher. 6/
Since the LP.8.1 variety is under monitoring, WHO member countries will continue to investigate its behavior, particularly its ability to circumvent human immunity. 7/
While LP.8.1 variant isn't a cause for concern, COVID can still be severe for individuals. Vigilance and vaccination, especially for medically susceptible groups, are crucial to minimizing illness effect. 8/8
Researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations of Paxlovid, currently the most prescribed oral treatment. 1/
As with its predecessor, the new drug candidate, Jun13296, targets a different viral protein than Paxlovid does and works alone rather than in combination with another drug called ritonavir. 2/
This new compound, #Jun3296 is more potent than the 1st generation candidate. In animal studies, this 2nd-generation inhibitor still provides 90% protection at just one-third dose of the initial compound and significantly outperforms it in reducing viral loads in the lungs. 3/
SARS-CoV-2 spike protein binds fibrinogen, causing thrombo-inflammation, according to a recent study. The virus must bind to fibrinogen, but why? Could this relationship help the virus evolve? Could this cause post-COVID heart attacks? 1/
Scientists often think they grasp a virus's anatomy, tricks, and body movement. But occasionally, we discover something unexpected that radically transforms how we view an infection. 2/
Some strategies are well documented: antigenic drift, glycan shielding, immune suppression. But every so often, we stumble upon a novel mechanism that redefines our understanding of viral pathogenesis. 3/
COVID-19 increases the risk of autoimmune diseases including rheumatoid arthritis and type 1 diabetes. The virus alters the immune system in unknown ways, making it difficult to design medicines to prevent post-COVID autoimmunity. 1/
One leading hypothesis involves viral “molecular mimics”—proteins from the virus that resemble the body’s own proteins. These mimics may trigger an immune response against the virus but unintentionally cause the immune system to target healthy tissues as well. 2/
Thanks to recent advancements in data analysis and machine learning, scientists have now identified a set of SARS-CoV-2-derived molecular mimics that may play a role in initiating autoimmune responses. 3/
mRNA-COVID-19 vaccines train the 'long-term memory' of immune system
Researchers have determined that the novel mRNA-COVID-19 vaccines not only induce acquired immune responses such as antibody production, but also cause persistent epigenetic changes in innate immune cells 1/
Thus, vaccination with mRNA vaccines could lead to an enhanced immune response to future encounters with pathogens which are not specifically targeted by the vaccine. 2/
These findings reveal that mRNA vaccines cause epigenetic 'training' of innate immune cells, sustaining immunological response. Epigenetic alterations may enable long-lasting innate immunity that enhances acquired immune system protection. 3/
In a proof-of-concept study, people with cognitive impairment in #LongCOVID were found to have asymmetrical glymphatic dysfunction in the left hemisphere of the brain which also correlated with disruption of the blood-brain barrier (BBB). 1/
A group of researchers used special MRI techniques to assess perivascular spaces in the brain of 14 individuals with LongCOVID compared to 10 healthy controls. 2/
A significant reduction in the DTI-ALPS index—a measure of glymphatic function—in the left hemisphere of LongCOVID patients was found, indicating impaired waste clearance in the brain. 3/
Sugar coatings aren't only for candies; they also help viruses, like the ones that cause COVID-19, hide from their hosts' immune system.
Now, researchers have developed a universal vaccine that targets coronaviruses and the sugars that they use as cover. 1/
As demonstrated in animal studies, the vaccine removed sugar molecules from an area of a coronavirus spike protein that rarely mutates and created effective and plentiful antibodies to inactivate the virus. 2/
Researchers say that the premise of this research is simple: it's an effective vaccine that targets more than one coronavirus at a time, which will allow individuals to receive a single shot for protection against multiple infectious agents. 3/